Pfizer's Strategic Move: Avoiding Tariffs through U.S. Production
Pfizer can avoid 'Section 232' pharmaceutical tariffs by relocating production to the U.S. within a three-year grace period, said CEO Albert Bourla. Speaking at the White House with President Trump, this came after a deal focused on drug prices was struck between Pfizer and the Trump administration.
Devdiscourse News Desk | Washington DC | Updated: 30-09-2025 22:10 IST | Created: 30-09-2025 22:10 IST
- Country:
- United States
Pfizer, a major U.S. drugmaker, can sidestep 'Section 232' pharmaceutical tariffs by shifting its production to the United States during a three-year window, according to CEO Albert Bourla.
Bourla made the announcement at the White House during an Oval Office event with U.S. President Donald Trump.
This statement follows a negotiated agreement on drug pricing between the pharmaceutical giant and the Trump administration.
Advertisement
ALSO READ
White House Restores Key Advisory Board for Nuclear Workers' Health Claims
PM Narendra Modi welcomes US President Donald Trump's announcement of a comprehensive plan to end Gaza conflict.
Google's YouTube to pay USD 24.5 million to settle 2021 lawsuit by Donald Trump over account suspension, reports AP.
White House Unveils Ambitious Peace Plan for Gaza
Historic White House Peace Proposal for Gaza
Google News